Surfactants preparations for preterm infants with respiratory distress syndrome: past, present, and future.

Surfactants preparations for preterm infants with respiratory distress syndrome: past, present, and future. Korean J Pediatr. 2019 Feb 08;: Authors: Jeon GW Abstract After the first successful trial of surfactant replacement therapy for preterm infants with respiratory distress syndrome (RDS) by Fujiwara in 1980, several animal-derived natural surfactants and synthetic surfactants have been developed. Synthetic surfactants were made to overcome limitations of natural surfactants such as expensiveness, immune reactions, and infections due to animal proteins contained in natural surfactants. However, first-generation synthetic surfactants that are protein-free have failed to prove superiority over natural surfactants because they do not have surfactant protein (SP). Lucinactant, a second-generation synthetic surfactant containing analog of SP-B, was better or at least as effective as natural surfactant, suggesting that lucinactant could be used as an alternative to natural surfactants. Lucinactant was approved by US FDA in March 2012 as a fifth surfactant to treat neonatal RDS. CHF5633, a second-generation synthetic surfactant containing analogues of both SP-B and SP-C, was effective and safe in human multicenter cohort study for preterm infants. Many comparative studies of natural surfactants used worldwide have reported different efficacies according to preparations. However, these differences are believed to due to site variations, ...
Source: Korean Journal of Pediatrics - Category: Pediatrics Tags: Korean J Pediatr Source Type: research